Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 11/20 | 0.44 |
| ▸ | FNTB | P49356 | 11/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 10/20 | 0.44 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396405 | 0.99 | FNTA (0.45) | DPP7FNTAFNTBPGGT1BRRM1 | |
| SCHEMBL13396409 | 0.86 | MEN1 (0.40) | DPP7FNTAFNTBPGGT1BRRM1 | |
| SCHEMBL13397027 | 0.82 | DPP7 (0.43) | DPP7FNTAFNTBPGGT1BRRM1 | |
| SCHEMBL13396425 | 0.82 | GNAI3 (0.58) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL13396454 | 0.82 | DPP7 (0.43) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL13396346 | 0.81 | CA12 (0.39) | — | |
| SCHEMBL13396361 | 0.81 | DPP7 (0.41) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL13396480 | 0.81 | RRM1 (0.43) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL13396495 | 0.81 | GNAI3 (0.60) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL13397198 | 0.81 | NOD1 (0.43) | DPP7FNTAFNTBRRM1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | DPP7 3437/4885FNTA 476/4885FNTB 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.